Volume 76, Issue 2 pp. 369-371
Full Access

Corticosteroid Treatment of Maternal ITP and Risk of Neonatal Thrombocytopenia

M. DONNÉR

Corresponding Author

M. DONNÉR

Departments of Paediatrics Obstetrics, University Hospital, Lund, Sweden

(M.D.) Department of Paediatrics University Hospital S-22185 Lund SwedenSearch for more papers by this author
S. ARONSSON

S. ARONSSON

Departments of Paediatrics Obstetrics, University Hospital, Lund, Sweden

Search for more papers by this author
L. HOLMBERG

L. HOLMBERG

Departments of Paediatrics Obstetrics, University Hospital, Lund, Sweden

Search for more papers by this author
P. OLOFSSON

P. OLOFSSON

Departments of Gynaecology, University Hospital, Lund, Sweden

Search for more papers by this author
First published: March 1987
Citations: 2

Abstract

ABSTRACT. Maternal ITP is associated with a high risk of thrombocytopenia in the fetus and newborn infant. Methods of predicting this risk include determinations of maternal platelet count and platelet-associated IgG prior to delivery. In this report we show that prednisolone treatment normalized maternal platelet count and platelet-associated IgG without eliminating circulating platelet antibodies, which thus crossed the placenta and rendered the infant severely thrombocytopenia. Determination of maternal circulating platelet antibodies may be the best way of predicting infant thrombocytopenia, especially if the mother has received corticosteroids.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.